Teoxane SA - 06 Jan 2025 SCHEDULE 13D/A Report for Revance Therapeutics, Inc. Common Stock, par value $0.001 per share (RVNC)

Filing Manager: Teoxane SA
Reporting Manager: Teoxane SA
Security: Revance Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol: RVNC
Shares outstanding: 105,658,065 shares
Disclosed Ownership: 6,550,800 shares
Ownership: 6.2%
Form type: SCHEDULE 13D/A
Filing time: 06 Jan 2025, 09:00:47 UTC
Date of event: 06 Jan 2025
Previous filing: 19 Dec 2024
Next filing: 30 Jan 2025
SEC: View on sec.gov

Reporting Managers (1)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
Teoxane SA	6.2%	6,550,800	6,550,800	0	/s/ Patrice Calvayrac	Patrice Calvayrac/ Chief Financial Officer	0001992112